News
Bloomberg on MSN3h
Novo CFO: US Wegovy, Ozempic Prices to Keep FallingThe maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Earlier this year, the Centers for Medicare and Medicaid Services scrapped a previous proposal, from the Biden administration ...
A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.
Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results